Marubi(SH:603983) Zheng Quan Shi Bao Wang·2025-10-31 01:21Core Insights - The company reported a revenue of 2.45 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 22.51% [1] - The net profit attributable to the parent company reached 244 million yuan, with R&D expenses amounting to 62.79 million yuan [1] - The net cash flow from operating activities significantly increased by 132.19% year-on-year, totaling 159 million yuan, indicating improved cash flow adequacy [1] Company Developments - In Q3 2025, the company submitted 32 patent applications and played a key role in formulating 4 standards, while also publishing 2 group standards, focusing on advanced technology areas such as collagen restructuring and active substance detection [1] - The company was awarded the qualification for the Guangdong Provincial Engineering Research Center for Recombinant Functional Proteins, marking a significant recognition following the establishment of the "National Recombinant Functional Protein Technology Research Center" in 2024 [1] - In September, the company received official recognition as a provincial-level postdoctoral innovation practice base, enhancing its capability in talent cultivation in the biotechnology field and promoting collaboration between industry and academia [1]